- Q1 2025 PetVivo Holdings Inc Earnings Call TranscriptAug 14, 2024$0.56208 (+14.71%)Earnings
- Q4 2024 PetVivo Holdings Inc Earnings Call TranscriptJun 28, 2024$0.52Earnings
- Q1 2024 PetVivo Holdings Inc Earnings Call TranscriptAug 10, 2023$2.45 (+22.50%)Earnings
- Q4 2023 PetVivo Holdings Inc Earnings Call TranscriptJun 30, 2023$1.97 (-17.23%)Earnings
- PetVivo Holdings Inc To Present at Aegis Capital Virtual Conference TranscriptMay 03, 2023
- Q3 2023 PetVivo Holdings Inc Earnings Call TranscriptFeb 09, 2023$2.94 (+1.38%)Earnings
- Q2 2023 PetVivo Holdings Inc Earnings Call TranscriptNov 10, 2022$2.43 (+6.11%)Earnings
- Q1 2023 PetVivo Holdings Inc Earnings Call TranscriptAug 11, 2022$2.22 (-1.33%)Earnings
- Q4 2022 PetVivo Holdings Inc Earnings Call TranscriptJun 29, 2022$2.05 (-11.64%)Earnings
- PetVivo Holdings Inc at Precious Metals Summit Planet Microcap Showcase TranscriptMay 03, 2022
- Q3 2022 PetVivo Holdings Inc Earnings Call TranscriptFeb 10, 2022$1.54 (+12.87%)Earnings
- PetVivo Holdings Inc at Emerging Growth Conference TranscriptJan 19, 2022
- Q2 2022 PetVivo Holdings Inc Earnings Call TranscriptNov 15, 2021Earnings
PetVivo Holdings Inc at Precious Metals Summit Planet Microcap Showcase Transcript
Thank you. Good afternoon, and I'm the CEO of PetVivo Holdings. There's a lot of information on this powerpoint, so I'm going to go extremely fast. This powerpoint is also available on our website. So we meet all the reg FD requirements. We trade under the symbol PETV on NASDAQ. There are forward-looking statements within this presentation.
So basically, we developed a protein particle-matrix that mimics cartilage and tissue. It has multiple applications within the companion animal space as well as in the human space. So the particles is a patented technology. We call it OsteoCushion technology, and the initial product is for the treatment -- for the use in the osteoarthritis market and we call it Spryng. So it's a very disruptive and effective tool in the treatment or in the use of osteoarthritis.
The product sells under $11 billion companion animal veterinary care market. And it's just not specifically for osteoarthritis, it's also for other joint afflictions and in certain cases, for rehab. So after surgery, doctors have
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)